Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091141 · ClinicalTrials.gov registry record · Phase 2
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 673
- Enrollment target
NCT02091141 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 673 participants.
The verdict
NCT02091141, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 673 participants
- Enrollment target
Study Summary
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.
Interventions
- DRUG Trastuzumab
- DRUG Vemurafenib
- DRUG Pertuzumab
- DRUG Cobimetinib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 673 participants |
| Start Date | 2014-04-14 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091141
The ClinicalTrials.gov registry entry for NCT02091141 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 673 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02091141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02091141 about?
NCT02091141 is a clinical study titled "My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors". This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.
What is the current status of trial NCT02091141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 673 participants. The study started on 2014-04-14. Estimated completion is 2023-05-24.
What interventions are being tested in trial NCT02091141?
The interventions under investigation include: Trastuzumab (DRUG), Vemurafenib (DRUG), Pertuzumab (DRUG), Cobimetinib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT02091141?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.